We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-16.69%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$2.07B
AUM Growth
-$429M
Cap. Flow
+$142M
Cap. Flow %
6.88%
Top 10 Hldgs %
44.14%
Holding
87
New
6
Increased
22
Reduced
12
Closed
8

Top Buys

Rank Stock Value
1
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$137M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$48.1M
3
CNTA
Centessa Pharmaceuticals
CNTA
+$32.9M
4
RPTX
Repare Therapeutics
RPTX
+$28.7M
5
CGEM icon
Cullinan Oncology
CGEM
+$24.3M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$99.7M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$64.9M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$37.2M
4
NGM
NGM Biopharmaceuticals, Inc. Common Stock
NGM
+$14.6M
5
GBIO
Generation Bio
GBIO
+$8.15M

Sector Composition

Rank Sector Weight
1 Healthcare 99.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
76
Voyager Therapeutics
VYGR
$185M
$827K 0.04%
140,000
-1,049,100
-88% -$7.09M
XFOR icon
77
X4 Pharmaceuticals
XFOR
$379M
$818K 0.04%
28,263
– –
RZLT icon
78
Rezolute
RZLT
$455M
$616K 0.03%
190,815
– –
NEUP
79
Neuphoria Therapeutics
NEUP
$21.1M
$555K 0.03%
6,748
– –
ABOS icon
80
Acumen Pharmaceuticals
ABOS
$159M
– –
-289,663
Closed -$1.13M
ARGX icon
81
argenx
ARGX
$53.8B
– –
-316,204
Closed -$99.7M
DAWN
82
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-809,282
Closed -$8.03M
LKFT
83
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.8B
– –
-1,046,283
Closed -$64.9M
NGM
84
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
– –
-955,000
Closed -$14.6M
JNCE
85
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
– –
-126,797
Closed -$861K
RDUS
86
DELISTED
Radius Health, Inc.
RDUS
– –
-378,000
Closed -$3.34M
GNCA
87
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-4,012,404
Closed -$5.02M
1 2 3
4

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2022 Portfolio in Review

As of Q2 2022, BVF Inc held 87 positions worth $2.07B, down 17% from $2.5B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

BVF Inc deployed $142M of net new capital in Q2 2022, opening 6 new positions and adding to 22 existing holdings. Its largest new stake was MoonLake Immunotherapeutics: 21,751,284 shares worth $114M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $37.2M trimmed.

  • BVF Inc's largest Q2 2022 buy was MoonLake Immunotherapeutics: 21,751,284 shares worth $114M.
  • BVF Inc added most to Centessa Pharmaceuticals in Q2 2022, an estimated $32.9M increase.
  • BVF Inc's biggest Q2 2022 reduction was Protagonist Therapeutics, cutting an estimated $37.2M.
  • BVF Inc fully exited argenx in Q2 2022, selling an estimated $99.7M.
  • BVF Inc's ten largest holdings make up 44% of its $2.07B portfolio in Q2 2022.
  • BVF Inc opened 6 new positions and closed 8 in Q2 2022.
  • BVF Inc's portfolio value fell 17% quarter-over-quarter to $2.07B.

Based on BVF Inc's 13F filing for Q2 2022, filed 15 Aug 2022.